← Back to Search

Tetracycline Antibiotic

Minocycline for High Blood Pressure

Phase 2
Waitlist Available
Led By Carl Pepine, MD
Research Sponsored by University of Florida
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
History of intestinal surgery, inflammatory bowel disease, celiac disease, lactose intolerance, chronic pancreatitis or other malabsorption disorder
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change in baseline to 24 weeks
Awards & highlights

Summary

This trial will test whether minocycline, which is used to treat hypertension, is associated with a decrease in activated microglia in central nervous system autonomic regions.

Who is the study for?
This trial is for individuals with drug-resistant high blood pressure who are already part of another study (NCT02133885). Participants must be willing to travel to Montreal, Canada for brain imaging and testing. They should not be pregnant or have been so in the last 6 months, nor taking certain medications that could affect the study's outcome.
What is being tested?
The trial is studying whether Minocycline can lower blood pressure by reducing microglia activation in the brain. This will be measured using advanced imaging techniques like PET and MRI scans alongside Autonomic Nervous System Testing.
What are the potential side effects?
While specific side effects are not listed here, Minocycline commonly causes dizziness, fatigue, headache, unsteadiness, and may affect digestion. It can also lead to changes in skin color and serious allergic reactions.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a history of digestive system issues or surgeries.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change in baseline to 24 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and change in baseline to 24 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
MRI changes in the paraventricular nucleus
PET changes in the paraventricular nucleus

Side effects data

From 2016 Phase 4 trial • 10 Patients • NCT02124811
40%
Inpatient psychiatric hospitalization
20%
Hospitalization due to ischemic colitis
20%
Hypotension
100%
80%
60%
40%
20%
0%
Study treatment Arm
Low CRP
High CRP

Trial Design

1Treatment groups
Experimental Treatment
Group I: MinocyclineExperimental Treatment1 Intervention
Subjects will receive the dose of Minocycline determined to best lower BP and will undergo baseline and week 12-24 follow-up MRI and PET scans for changes in the paraventricular nucleus.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Minocycline
2019
Completed Phase 4
~1070

Find a Location

Who is running the clinical trial?

University of FloridaLead Sponsor
1,384 Previous Clinical Trials
762,578 Total Patients Enrolled
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,905 Previous Clinical Trials
47,837,648 Total Patients Enrolled
Carl Pepine, MDPrincipal InvestigatorUniversity of Florida
6 Previous Clinical Trials
216 Total Patients Enrolled

Media Library

Minocycline (Tetracycline Antibiotic) Clinical Trial Eligibility Overview. Trial Name: NCT02213575 — Phase 2
High Blood Pressure Research Study Groups: Minocycline
High Blood Pressure Clinical Trial 2023: Minocycline Highlights & Side Effects. Trial Name: NCT02213575 — Phase 2
Minocycline (Tetracycline Antibiotic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02213575 — Phase 2
~4 spots leftby Apr 2025